Showing 6651-6660 of 9501 results for "".
- ASDS Database Helps Residents Find Fellowships and Opportunitieshttps://practicaldermatology.com/news/20130716-asds_database_helps_residents_find_fellowships_and_opportunities/2459499/To help residents with the challenge of identifying suitable fellowship programs, the American Society for Dermatologic Surgery's (ASDS) new database, called the DermSurg Fellowship Finder, is a comprehensive source for all Mohs, procedural, cosmetic, and laser surgical fellowships in the US. The go
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- Artefill Shows Efficacy for Atrophic Acne Scars: Datahttps://practicaldermatology.com/news/20130624-artefill_shows_efficacy_for_atrophic_acne_scars_data/2459513/Recently reported data suggest that ArteFill dermal filler is an effective option to treat atrophic acne scars. Suneva Medical shared promising six-month results from its randomized, double-blinded, multi-center, controlled study that evaluated the
- Avène SPF Awarded Skin Cancer Foundation Seal Of Recommendationhttps://practicaldermatology.com/news/20130611-avne_spf_awarded_skin_cancer_foundation_seal_of_recommendation/2459517/The Skin Cancer Foundation approved Avène High Protection Tinted Compact SPF 50 in both shades (Beige and Honey) to carry The Skin Cancer Foundation Active Seal of Recommendation. The coveted Seal signifies that these products have
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr